A5011388259- Gastroesophageal reflux and treatments
- Diabetes Treatment and Management
- Eosinophilic Esophagitis
- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal motility and disorders
- Diabetes Management and Research
- Health Systems, Economic Evaluations, Quality of Life
- Metabolism, Diabetes, and Cancer
- Medication Adherence and Compliance
- Glioma Diagnosis and Treatment
- Pharmacology and Obesity Treatment
- Biosimilars and Bioanalytical Methods
- Esophageal and GI Pathology
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Chronic Disease Management Strategies
- Diverticular Disease and Complications
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical studies and practices
- Epigenetics and DNA Methylation
- Diet and metabolism studies
- Congenital gastrointestinal and neural anomalies
Eli Lilly (United States)
2017-2025
Wilmington University
2010-2024
Ibero American University
2017-2022
Indianapolis Zoo
2021
Triangle
2021
University of California, Los Angeles
2012-2018
Nova Southeastern University
2017
Takeda (United States)
2009-2016
Deerfield (United States)
2009-2016
Takeda (Japan)
2009-2014
The GEMINI long-term safety [LTS] study is a continuing phase 3 trial investigating the and efficacy of vedolizumab, an α4β7 integrin antagonist for ulcerative colitis [UC] Crohn’s disease. We provide interim analysis in patients with UC. Patients from C13004 1 studies cohort vedolizumab-naïve received open-label vedolizumab every 4 weeks. Interim data were collected May 22, 2009 to June 27, 2013. Clinical response remission, evaluated using partial Mayo scores, health-related quality life...
Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial an ongoing open-label study investigating the of vedolizumab. We present interim exploratory analyses efficacy in patients with Patients from C13004, 2 3 studies vedolizumab-naïve could enrol LTS received vedolizumab every 4 weeks. Data were collected May 22, 2009 to June 27, 2013. Outcomes clinical response remission, defined by Harvey-Bradshaw...
Chronic constipation (CC) is a highly prevalent health problem, potentially associated with increased risk of colorectal cancer (CRCancer).To investigate the association between CC, its severity, and CRCancer by estimating relative developing benign neoplasm (BCN) among severity-stratified patients without CC.Chronic from large retrospective US claims database were matched 1:3 CC-free controls demographic characteristics. BCN prevalence measured over 1 year. In pre-index CRCancer- BCN-free...
Aims To compare adherence (proportion of days covered [ PDC ]), persistence, and treatment patterns among patients with type 2 diabetes mellitus ( T2DM ) newly initiating glucagon‐like peptide‐1 receptor agonists GLP‐1RAs ). More specifically, the main objectives were to dulaglutide vs exenatide once weekly liraglutide. Methods Patients dulaglutide, albiglutide, weekly, twice daily liraglutide between N ovember 2014 A pril 2015 hierarchically selected from T ruven H ealth's MarketScan R...
Abstract Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy tirzepatide 5/10/15 mg versus semaglutide 2 in patients with type diabetes. Materials and Methods The primary analysis was a Bucher aITC change from baseline at week 40 HbA1c (%) body weight (kg). Aggregate data SURPASS‐2 study that met inclusion criterion SUSTAIN FORTE metformin‐only treated were used for analysis. Results refined population comprised 238/245/240 240 participants 1 mg, respectively. 222...
Studies that compare prostate cancer treatment costs show wide variation. None all contemporary costs, and most focus on initial costs. The authors compared healthcare utilization cost patterns of treatments over a span 5.5 years in 4553 newly diagnosed patients stratified by age risk group.Contemporary evaluation for were identified using CaPSURE, national disease registry men with included ongoing clinical data collection from 31 academic community urology practices biennial...
Gout is a common cause of inflammatory arthritis in the United States, and its prevalence has increased recent decades, especially among older adults. Older adults with gout are particular interest because they tend to experience higher rates tophi, an advanced stage gout, than do younger patients.For (1) assess health care utilization costs from third-party payer perspective; (2) evaluate related tophi; (3) explore relationship between elevated serum uric acid (UA) level, indicator disease...
Increased serum urate (sUA) levels (> or =6.0 mg/dL) are associated with increased likelihood of acute gout attacks, "flares."Identify flares administrative claims data; examine the relationship between sUA and flares; association flare-related costs.This retrospective analysis examined subjects =2 medical ICD-9-CM diagnosis code 274.xx > =1 claim a pharmacy for allopurinol, probenecid, colchicine, sulfinpyrazone) January 1, 2002 March 31, 2004. Each subject was observed during 1-year...
Summary Background Treatments for Crohn's disease ( CD ) and ulcerative colitis UC are not uniformly effective, thus necessitating dose changes, switching, augmentation carry adverse event risk, often requiring discontinuation, which reduces treatment benefits. Aim To assess continuity of changes to initial treatments, as well costs associated with specific parameters defining suboptimal therapy. Methods Commercial US insurance claims (2006–2010) were retrospectively analysed. patients...
OBJECTIVES: Nocturnal heartburn and related sleep disturbances are common among patients with gastroesophageal reflux disease (GERD). This study evaluated the efficacy of dexlansoprazole MR 30 mg in relieving nocturnal GERD-related disturbances, improving work productivity, decreasing symptom severity symptomatic GERD. METHODS: Patients (N=305) frequent, moderate-to-very severe associated were randomized 1:1 a double-blind fashion to receive or placebo once daily for 4 weeks. The primary end...
Aims To evaluate adherence, persistence, glycaemic control and costs at 12‐month follow‐up for patients initiating dulaglutide versus liraglutide or exenatide once weekly. Materials methods The present retrospective observational claims study included with type 2 diabetes (T2D) ≥ 1 pharmacy claim dulaglutide, weekly from the HealthCore Integrated Research Database. Adherence was defined as proportion of days covered ≥80%, persistence measured by time to discontinuation index therapy. Change...
Abstract Aims To understand patient preferences for once‐daily oral versus once‐weekly injectable type 2 diabetes mellitus (T2DM) medication administration profiles, and reasons their preferences. Materials methods The REVISE study, a cross‐sectional online survey of 600 participants with T2DM (United Kingdom, n = 300; United States, 300), elicited general medications, the preference. Participants then viewed two videos describing procedures dulaglutide semaglutide, based on product...
The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established disease. This exploratory analysis evaluated the degree which effect of dulaglutide on could statistically account for its effects major adverse events (MACE) in trial.Potential mediators that were significantly reduced by assessed a post hoc using repeated measures mixed models included glycated hemoglobin (HbA1c), body weight, waist-to-hip ratio, systolic...
Objective. We examined the association between serum uric acid (SUA) level and frequency, risk, cost of gout flares among elderly. Methods. Data were extracted from Integrated Healthcare Information Services claims database (1999–2005). Patients included if they had gout, aged 65 years older both medical pharmacy benefits, electronic laboratory data. with gouty episodes identified using algorithms based on ICD-9-CM codes medications. Logistic regression negative binomial regressions used to...
To determine the association between allopurinol compliance and serum urate (sUA) level; examine sUA gout-related healthcare costs in a large managed care population.This retrospective administrative claims analysis examined subjects with gout (> or = 2 medical ICD-9-CM diagnosis code 274.xx > 1 claim pharmacy for allopurinol, probenecid, colchicine, sulfinpyrazone) January 1, 2002 March 31, 2004. Each subject was observed during 1-year pre-index post-index periods.Outcomes were medication...
Objectives:Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Prevalence estimates of IBS vary widely, from 10 to 15%, in the U.S. However, few studies have examined constipation predominant (IBS-C), subtype IBS. The aim this study was assess effect IBS-C on health-related quality life (HRQOL), work productivity and activity impairment, health care resource use.
Mutations in isocitrate dehydrogenase 1 (IDH1) and associated CpG island hypermethylation represent early events the development of low-grade gliomas secondary glioblastomas. To identify candidate tumor suppressor genes whose promoter methylation may contribute to gliomagenesis, we compared profiles IDH1 mutant (MUT) wild-type (WT) tumors using massively parallel reduced representation bisulfite sequencing. Reduced sequencing was performed on ten pathologically matched WT MUT glioma samples...
To assess glycemic effectiveness, adherence and persistence within 6 months of treatment initiation with dulaglutide, a once weekly GLP-1 receptor agonist, in US real-world setting.This retrospective claims analysis included adults (≥18 years) T2DM from the HealthCore Integrated Research Database, who had HbA1c laboratory results around after initiation. Glycemic control was assessed by change pre-initiation to post-initiation. Patients were considered adherent if their proportion days...
Abstract Aim To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 on body weight in patients with type 2 diabetes (T2D) based exploratory analyses AWARD‐11 trial. Materials Methods Patients were randomized to once‐weekly (n = 612), 616) or 614) for 52 weeks. The primary objective was superiority and/or over HbA1c reduction at 36 Secondary assessments included overall trial population baseline mass index (BMI) subgroups. Results At baseline, had a mean age 57.1 years, 8.6% (70...
The study objective was to describe characteristics and utilization patterns of tirzepatide users with type 2 diabetes (T2D) using the Healthcare Integrated Research Database in USA. Adults (≥18 years) included had T2D diagnosis; ≥1 claim (May 2022–January 2023; first date = index date); continuous medical pharmacy enrollment during 6-month baseline follow-up periods from date. Baseline demographics, clinical characteristics, dosing treatment were summarized descriptively. 15,665 patients...